目的 通過ip角叉菜膠（Ca）溶液建立小鼠慢性尾部血栓模型，尾iv給予注射用丹參多酚酸（SAFI），探究其抗炎癥血栓作用。方法 將168只KM雄性小鼠隨機(jī)分為6組：對(duì)照組，模型組，SAFI低、中、高劑量（8.365、16.730、33.460 mg·kg^-1）組，造模同時(shí)給藥組（即造模的同時(shí)予以SAFI給藥，其余組于造模后給藥，16.730 mg·kg^-1）。連續(xù)4 d ip 0.06% Ca（10 mL·kg^-1）制備血栓模型，4 d后，對(duì)照組和模型組尾iv 0.9%氯化鈉注射液，其余各組分別尾iv相應(yīng)劑量的SAFI，每天1次，給藥7 d。給藥開始后每天記錄各組小鼠的出栓情況；給藥結(jié)束后各組小鼠摘眼球取血，試劑盒法檢測(cè)血清中6-酮-前列腺素F1α（6-keto-PGF1α）、血栓素B2（TXB2）、腫瘤壞死因子-α（TNF-α）、白細(xì)胞介素-6（IL-6）、白細(xì)胞介素-1β（IL-1β）水平，取尾部組織進(jìn)行病理切片，HE染色觀察組織損傷。結(jié)果 模型組小鼠出栓率隨時(shí)間延長(zhǎng)增加，在給藥第5天出栓率達(dá)到100%；SAFI各劑量組小鼠出栓率均低于同一天的模型組，且低、中、高劑量組小鼠出栓率結(jié)果存在一定的劑量相關(guān)性；造模同時(shí)給藥組出栓率均低于同一天的模型組，且相比于同一劑量（中劑量組）出栓率更低。與模型組比較，SAFI中、高劑量組和造模同時(shí)給藥組血清中TXB2水平顯著降低（P＜0.05、0.01、0.001），6-keto-PGF1α水平顯著升高（P＜0.01、0.001）； SAFI低劑量組小鼠血清IL-6水平顯著降低（P＜0.05），中、高劑量組和造模同時(shí)給藥組小鼠血清TNF-α、IL-1β、IL-6水平顯著降低（P＜0.05、0.01、0.001）； SAFI高劑量組、造模同時(shí)給藥組血栓情況均明顯改善。結(jié)論 ip 0.06% Ca制備的炎癥血栓小鼠模型穩(wěn)定、可靠，SAFI能改善炎癥血栓小鼠血清中6-keto-PGF1α、TXB2、IL-6、IL-1β、TNF-α水平，有效緩解炎性因子導(dǎo)致的血栓癥狀。

Objective Chronic thrombus model was established by ip injection of carrageenan (Ca) solution in mice, and then Salvianolic Acid for Injection (SAFI) was given to investigate its anti-inflammatory thrombus effect. Methods 168 KM male mice were randomly divided into seven groups: Control group, model group, SAFI low, medium, and high-dose (8.365, 16.730, and 33.460 mg·kg^-1) group, model making and drug administration group (i.e. model making and drug administration were conducted simultaneously, while the other groups were administered after model making, 16.730 mg·kg^-1). The thrombus model was prepared by ip 0.06% Ca for four consecutive days. After four days, the corresponding dose of SAFI was administered to the other groups, except for the control group and the model group iv 0.9% sodium chloride injection. The thrombolysis of each group of mice was recorded every day after the beginning of administration. Blood was removed from the eyeballs of each group and 6-ketoprostaglandin1α (6-keto-PGF1α), thromboxane (TXB2), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β) levels in serum were detected by kits. After the experiment, the tail tissue was taken for pathological section, and the tissue damage was observed by HE staining. Results The incidence of thrombosis in the model group increased with time, reaching 100% on the 5th day of administration. The incidence of thrombosis in mice of each dose group of SAFI was lower than that of the model group on the same day, and there was a certain dose correlation between the incidence of thrombosis in mice of low, medium, and high dose groups. The incidence of thrombosis in the simultaneous administration group was lower than that in the model group on the same day, and lower compared to the same dose (medium dose group). Compared with the model group, the serum TXB2 levels in the SAFI medium and high dose groups, as well as the simultaneous administration of models, were significantly reduced (P＜0.05, 0.01, 0.001), with the level of 6-keto-PGF1α significantly increased (P＜0.01, 0.001). The serum IL-6 levels in the low-dose SAFI group of mice were significantly reduced (P＜0.05), while the serum of TNF-α, IL-1 β, and IL-6 in the medium, high-dose, and simultaneous administration group groups were also significantly decreased (P＜0.05, 0.01, 0.001). The thrombosis situation was significantly improved in the high-dose SAFI group and the simultaneous administration group. Conclusion The mice model of inflammatory thrombus prepared by ip injection of 0.06% Ca was stable and reliable. SAFI can improve the levels of 6-keto-PGF1α, TXB2, IL-6, IL-1β and TNF-α in the serum of mice with inflammatory thrombus, and effectively relieve the symptoms of thrombus caused by inflammation.

R285.5